Transaction DateRecipientSharesTypePriceValue
10th December 2020Target N V Biotech150,000Open or private purchase$8.39$1,258,425.00
10th December 2020Target N V Biotech170,000Open or private purchase$8.18$1,391,416.00
9th December 2020Target N V Biotech125,000Open or private purchase$8.62$1,077,600.00
10th November 2020Target N V Biotech80,000Open or private purchase$9.16$732,472.00
9th November 2020Target N V Biotech80,000Open or private purchase$9.05$724,144.00
6th November 2020Target N V Biotech470,335Open or private purchase$8.33$3,919,960.02
5th November 2020Target N V Biotech75,000Open or private purchase$10.86$814,230.00
5th November 2020Target N V Biotech100,000Open or private purchase$14.26$1,426,230.00
3rd November 2020Target N V Biotech200,000Open or private purchase$25.31$5,062,120.00
30th October 2020Target N V Biotech80,000Open or private purchase$8.83$706,312.00
Molecular Templates
Molecular Templates logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.

Molecular Templates, Inc. was founded on October 17, 2001 and is headquartered in Austin, TX. The company utilizes its proprietary biologic drug platform to design and generate engineered toxin bodies.

Ticker: MTEM
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1183765
Employees: 168
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Analysis of subtle changes in disclosure language. Red is a sign of more constrained, less positive language changes etc. Green is more positive, less constrained etc.
Red Flags
Red Flag analysis based on Klaus Henselmann / Elisabeth Scherr paper
Fundamentals
Cash at Carrying Value: $28 M (0%)
Marketable Securities, Current: $63 M (59%)
Other Assets, Current: $160 Th (-67%)
Assets, Current: $108 M (-22%)
Property, Plant and Equipment, Net: $20 M (0%)
Other Assets, Noncurrent: $5 M (3%)
Assets: $142 M (-18%)
Accounts Payable, Current: $2 M (13%)
Accrued Liabilities, Current: $14 M (0%)
Liabilities, Current: $41 M (15%)
Long-term Debt, Excluding Current Maturities: $15 M (400%)
Other Liabilities, Noncurrent: $1 M (4%)
Liabilities: $87 M (21%)
Common Stock, Value, Issued: $46 Th (0%)
Common Stock, Shares, Issued: $46 M (0%)
Additional Paid in Capital, Common Stock: $273 M (2%)
Retained Earnings (Accumulated Deficit): $217 M (32%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $172 Th (855%)
Stockholders' Equity (Parent): $56 M (0%)
Liabilities and Equity: $142 M (-18%)
Research and Development: $30 M (-40%)
General and Administrative Expenses: $6 M (-46%)
Operating Income/Loss: $30 M (-42%)
Red Flag analysis based on Klaus Henselmann / Elisabeth Scherr paper
News
Generic placeholder
ARTMS und Isotopia Molecular Imaging melden erfolgreiche Multi-Curie-Markierung von PSMA-11 mit zyklotron-produziertem 68Ga mithilfe des QUANTM Irradiation System™ und festen Targets

19th January 2021

Generic placeholder
ARTMS e Isotopia Molecular Imaging anuncian el rotulado exitoso de PSMA-11 de múltiples curies con Ga 68 producido con ciclotrón que utiliza QUANTM Irradiation System™ y objetivos sólidos

19th January 2021

Generic placeholder
Riassunto: ARTMS e Isotopia Molecular Imaging annunciano la riuscita marcatura multicurie di PSMA-11 con 68Ga prodotto in ciclotrone utilizzando QUANTM Irradiation System™ e target solidi

19th January 2021

Generic placeholder
Samenvatting: ARTMS en Isotopia Molecular Imaging kondigen succesvolle multi-curie-etikettering van PSMA-11 aan met cyclotron geproduceerd 68Ga met behulp van het QUANTM Irradiation System™ en Solid Targets

19th January 2021

Generic placeholder
ARTMS et Isotopia Molecular Imaging annonce le marquage multi-curies du PSMA-11 avec du 68Ga produit en cyclotron à l'aide du QUANTM Irradiation System™ et de cibles solides

19th January 2021

Generic placeholder
Molecular Templates, Inc. Provides Update on MT-5111 Phase 1 Study

21st December 2020